Who typically evaluates regulatory risk during VC due diligence?
Venture capital firms place primary responsibility for assessing regulatory risk on the investment team led by partners and associates. Academic work by Paul A. Gompers Harvard Business School highlights that the investment team performs the initial, multidisciplinary scrutiny that informs a funding decision. That front-line analysis identifies obvious licensing, registration, or market-entry constraints and determines whether deeper, specialized review is required.
Specialized reviewers and external experts
After the investment team flags issues, external legal counsel and regulatory specialists usually take the lead. Silicon Valley law firms and national boutiques publish due-diligence frameworks used by VCs to investigate permits, intellectual property implications, and compliance histories; Cooley LLP and Wilson Sonsini are commonly cited advisers in early-stage transactions. In-house counsel at the startup, when available, provides operational context and documentation but external counsel supplies jurisdictional interpretation, statutory citations, and regulatory pathways. For highly regulated sectors — fintech, health care, energy, and biotech — VCs also engage subject-matter experts, former regulators, and technical consultants to evaluate practical enforceability and likely timeframes for approvals.
Relevance, causes, and consequences
Regulatory risk matters because it can convert a promising business model into an unscalable one. Research and industry reporting by CB Insights show that regulatory obstacles and legal challenges figure among common failure modes for startups. Common causes include unclear statutory fit for novel technologies, cross-border licensing gaps, and rapid regulatory change that outpaces a product’s commercialization plan. Consequences range from delayed market entry and costly remediation to fines, injunctions, or forced pivoting that erodes investor returns and harms market trust. Territorial nuance is crucial: a fintech product acceptable in one country may breach securities laws in another, while medical-device approvals hinge on region-specific clinical evidence and manufacturing controls.
Practical division of labor and cultural factors
In practice, evaluation is collaborative: investment partners set risk tolerances and commercial thresholds; legal teams identify hard prohibitions and mitigation strategies; and technical or regulatory consultants estimate timelines and compliance costs. VCs with deep sectoral experience often maintain networks of former regulators and local counsel to navigate cultural and territorial complexities, for example differing enforcement culture between the United States, the European Union, and emerging markets. That blend of investment judgement, legal expertise, and on-the-ground knowledge determines whether a regulatory issue is a manageable risk or a dealbreaker.